GHRP-2 Blend

Research indicates that GHRP-2 and CJC-1295 peptides may act on separate receptors, potentially enhancing the release of growth hormone (GH) from the anterior pituitary. GHRP-2 Blend.

GHRP-2 Blend

CJC-1295 is a molecular compound that exhibits an apparent binding affinity for the growth hormone-releasing hormone (GHRH) receptors, potentially inducing growth hormone release by pituitary cells. CJC-1295 is derived from GHRH 1-29, which is considered to represent the functional sequence of the initial 29 amino acids of GHRH. The peptide CJC-1295 has undergone tetra substitution and modification through the addition of a drug affinity complex (DAC) component. This DAC component appears to bind to plasma proteins and may enhance the pharmacokinetic profile of CJC-1295.

Growth Hormone Releasing Peptide 2 (GHRP-2) is a synthetic hexapeptide composed of six amino acids. Research teams have observed this peptide to bind to the ghrelin or growth hormone secretagogue 1a receptors (GHS-R1a), which are present in the hypothalamus and the pituitary gland. Consequently, GHRP-2 has been suggested by researchers to stimulate the production of growth hormones in pituitary cells that express the GHS-R1a receptor.

By stimulating different receptors through distinct biochemical pathways, these peptides are believed to synergistically elevate GH release from the anterior pituitary beyond the individual capacities of each peptide.